Marina Chiara Garassino
University of Chicago
H-index: 69
North America-United States
Top articles of Marina Chiara Garassino
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
NTRK gene fusion testing and management in lung cancer | Matteo Repetto Marina Chiara Garassino Herbert H Loong Fernando Lopez-Rios Tony Mok | 2024/4/3 | |
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial | Journal of Clinical Oncology | Daniel SW Tan Enriqueta Felip Gilberto de Castro Benjamin J Solomon Alastair Greystoke | 2024/1/10 |
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint … | Journal of Thoracic Oncology | Jacobi B Hines Robert B Cameron Alessandra Esposito Leeseul Kim Luca Porcu | 2024/3/8 |
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo-and chemo-immunotherapy | Journal of Experimental & Clinical Cancer Research | Gloriana Ndembe Ilenia Intini Massimo Moro Chiara Grasselli Andrea Panfili | 2024/1/2 |
Mesothelioma: Pleural, Version 1.2024: Featured Updates to the NCCN Guidelines | Journal of the National Comprehensive Cancer Network | James Stevenson David S Ettinger Douglas E Wood Dara L Aisner Wallace Akerley | 2024/3/1 |
Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer. | Jacobi B Hines Robert B Cameron Alessandra Esposito Leeseul Kim Luca Porcu | 2024 | |
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial | The Oncologist | Emilio Bria Floriana Morgillo Marina Chiara Garassino Fortunato Ciardiello Andrea Ardizzoni | 2024/2/20 |
Response to Letter to the Editor From Shaorong Yu and Jifeng Feng | Journal of Thoracic Oncology | Marina C Garassino Corinne Faivre-Finn | 2024/1/1 |
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund | Tumori Journal | Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo | 2024/2/19 |
Pembrolizumab Plus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes … | Journal of Thoracic Oncology | Shirish M Gadgeel Delvys Rodríguez-Abreu Balazs Halmos Marina C Garassino Takayasu Kurata | 2024/4/18 |
Durvalumab±Tremelimumab+ Platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden | Clinical Cancer Research | Luis Paz-Ares Marina Chiara Garassino Yuanbin Chen Niels Reinmuth Katsuyuki Hotta | 2024/2/16 |
34P Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC | Journal of Thoracic Oncology | F Griesinger MC Garassino E Felip H Sakai X Le | 2023/4/1 |
Brief report: discordance between liquid and tissue biopsy-based next-generation sequencing in lung adenocarcinoma at disease progression | Clinical Lung Cancer | Misha C Tran Garth W Strohbehn Theodore G Karrison Sherin J Rouhani Jeremy P Segal | 2023/5/1 |
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study. | Paul K Paik Marina Chiara Garassino Xiuning Le Michael Thomas Hiroshi Sakai | 2023/6/1 | |
Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, a multicenter, multicohort, open-label, phase 2 trial (cohort 4) | Journal of Thoracic Oncology | Robin Cornelissen Arsela Prelaj Sophie Sun Christina Baik Mirjana Wollner | 2023/8/1 |
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1 … | The Lancet Oncology | Mustafa Özgüroğlu Saadettin Kilickap Ahmet Sezer Mahmut Gümüş Igor Bondarenko | 2023/9/1 |
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT) | Lung Cancer | Laura Burns Chih-Yuan Hsu Jennifer G Whisenant Melina E Marmarelis Carolyn J Presley | 2023/12/1 |
1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial | Annals of Oncology | S Viteri E Felip F Griesinger MC Garassino H Sakai | 2023/10/1 |
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations | Clinical Lung Cancer | Marta Brambilla Teresa Beninato Anna Piemontese Laura Mazzeo Chiara Carlotta Pircher | 2023/11/1 |
ctDNA Dynamics, Prognostic Markers, and Mechanisms of Resistance in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial. | Journal of Oncology Navigation & Survivorship | Xiuning Le Marina Chiara Garassino Myung-Ju Ahn Enriqueta Felip Alexis B Cortot | 2023/11/1 |
